This paper provides practical guidance on the fundamentals of design for major randomized controlled trials. Topics covered include the choice of patients, choice of treatment and control groups, choice of primary and secondary endpoints, methods of randomization, appropriate use of blinding, and determination of trial size. Insights are made with reference to contemporary major trials in cardiology. (J Am Coll Cardiol 2015;66:2757-66) 
T he properly designed randomized controlled trial is recognized as providing the highest level of evidence in determining guidelines for therapeutic practice (1) . However, numerous pitfalls in trial design may occur, which, if succumbed to, may seriously impair the reliability of or confidence in the results. In this paper, we review the key features that determine whether a trial's design is "up to scratch." These fundamentals include: selection of patients, treatments, and outcomes; randomization methods; appropriate blinding; and determination of trial size, which are summarized in the Central Illustration. Of course, one first has to propose a relevant clinical question for which true equipoise exists.
Our focus is on major, pivotal (phase III) trials that are intended to directly influence clinical practice, and throughout we bring the issues to life with topical examples from recent cardiology trials. Our underlying intent is to elucidate matters of trial design that should be considered and clearly documented in a study protocol (2, 3) . Once the study protocol is finalized, it is good practice to register the trial on a website (prior to patient enrollment) and to make the protocol readily available. The core goals are to plan each trial so that it will achieve unbiased conclusions for treatment comparisons of direct public health relevance that are both clinically meaningful and statistically precise. It is fundamentally important to differentiate a statistically significant difference from a clinically meaningful difference. Very large studies may sometimes result in small, statistically significant differences in outcomes that have little or no clinical relevance. It is, of course, also essential that the trial can be successfully completed. That is, from ethical, scientific, organizational, and funding standpoints, the protocol is deliverable. This pragmatism underpins all that follows here.
CHOICE OF PATIENTS AND CENTERS
The delineation of precise eligibility criteria is important in determining the population of patients to which the trial findings can be extrapolated (3) .
Setting the criteria too specifically can inhibit successful patient recruitment and restrict generalizability, whereas unduly broad entry criteria may dilute the opportunity to identify a treatment effect in a specific population.
In acute coronary syndromes (ACS), the PLATO In chronic heart failure, the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) trial of candesartan had broad entry criteria with no entry ejection fraction restriction, although the investigators recognized that patients with preserved left ventricular systolic function should be interpreted as a separate stratum: CHARM Preserved (7, 8) . In contrast, the RALES (Randomized Aldactone Evaluation Study) trial of spironolactone focused on high-risk patients (history of New York Heart Association functional class IV and ejection fraction #35%). This facilitated using all-cause mortality as a realistic primary endpoint, but restricted the generalizability of the trial findings (9). Alternatively, some trials recruit only high-risk patients to achieve a sufficient number of outcome events, for example, (11, 12) , but then their generalizability is uncertain. The results of single-center trials may be unique to the specific practices and techniques used at that institution, adequate masking and absence of independent monitoring and core laboratories may be issues, resource commitment is often less than in multicenter trials, and treatment effect sizes can sometimes be at odds with multicenter investigations.
However, global trials raise other issues: problems of ensuring trial quality in all countries; issues with center-to-center variability and training; easier recruitment in certain regions (e.g., Eastern Europe), which affects the distribution of geographic representation; and concerns over geographic heterogeneity in treatment effect, as occurred in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial of spironolactone in preserved cardiac function heart failure ( Figure 1) (13) . Nonetheless, large-scale multicenter trials are preferable to single-center studies, with the understanding that the results apply to the geographies and practices of the participants. Secondary analysis should be undertaken to ensure that there are no major geographic disparities in the results (14) .
CHOICE OF TREATMENTS AND CONTROL GROUPS
In drug trials, usually the new treatment has 1 specific dose regimen that is selected on the basis of earlier research investigating the agent's safety profile, and surrogate endpoints are often used to evaluate efficacy. Occasionally, a major trial proceeds The appropriate choice of control group is crucial in trial design (17) . Many opt for a placebo control, whereby the new drug or placebo is assigned on top of current therapeutic practice, for example, CHARM and SHIFT (Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial) (assessing ivabradine) in chronic heart failure (7, 18) . This is common for regulatory trials; evidence for Food and Drug Administration approval can be straightforward, but in an advancing field such as heart failure, this means that patients face a growing polypharmacy with little evidence that any drugs get withdrawn from routine use (19) .
Opting for an active comparator poses additional challenges. For example, in the PARADIGM-HF 
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endpoints (e.g., blood pressure or glucose control).
Given the cost and complexity of pivotal randomized trials, there is increasing interest in considering surrogates as pivotal trial endpoints, but the criteria for true surrogacy are difficult, although not impossible, to achieve (23) . For example, angiographic late loss after coronary stent implantations has been demonstrated to be a surrogate for ischemia-driven target lesion revascularization (24) .
Although selection of which clinical events to collect follow-up data on may be straightforward, precise definitions are needed in the study protocol.
Furthermore, many trials have an independent events adjudication committee (25) (Table 1) .
However, what events should contribute to a composite primary endpoint? This depends on the disease and treatments being studied. In ACS and diabetes CV safety trials, the usual composite is CV death, MI, and stroke. Some are tempted to add in extra components, for example, including unstable angina or ischemia-driven revascularization into a broader major adverse CV events composite. This boosts the numbers of events but dilutes the effect and meaning of the composite. For instance, the most frequent (and often least clinically relevant) component tends to be the driver of event rates (e.g., enzymatic MIs or revascularization in ACS trials).
In chronic heart failure, the standard composite primary endpoint is CV death and hospitalization for heart failure. The weakness here is that it emphasizes the first hospitalization and ignores any subsequent hospitalizations or death thereafter. Greater insight and enhanced statistical power may be achieved by a primary endpoint analysis that incorporates both repeat hospitalizations for heart failure and CV death Several options exist for the analysis of repeat events (e.g., hospitalizations) in chronic disease (e.g., heart failure) trials and are illustrated in reanalyses of the CHARM and CORONA (Controlled Rosuvastatin
Multinational Trial in Heart Failure) trials (28, 30) . It is important to recognize that repeat events within a patient are not independent. For example, a few patients will have many hospitalizations, whereas many will have none at all. The negative binomial 
Analysis considerations
Emphasis usually on time to first event, which is often less serious (e.g., hospitalization) than subsequent events (e.g., death). Always show results for each separate component. Methods exist for repeat events and for competing risks, but complexity is a challenge. Win ratio method prioritizes events of greater clinical importance.
Pocock et al. terms, a specific set of secondary outcomes and use a statistical correction for multiplicity (e.g., the Hochberg procedure [37] ) in determining which endpoints meet criteria as "positive." If a method to control for multiplicity was not pre-specified, the data with confidence intervals should just be presented and clearly identified as secondary outcomes. Although the implications from such secondary endpoints should usually be considered exploratory and hypothesis generating, they still may provide a persuasive level of evidence if highly positive (e.g., p < 0.001).
Because patient-centered outcomes and economic evaluations are of increasing importance, secondary outcomes may also include quality of life, patient preferences, and resource utilization data.
METHODS OF RANDOMIZATION
The justification for randomization and the problems in interpreting nonrandomized treatment comparisons are well known (38, 39) . Herein, we discuss the actual methods of setting up and delivering random allocation of patients to treatments (Table 2) (40).
There are 3 key elements: 1) the statistical methods used to set up the sequence of randomized treatment assignments; 2) the practical means by which the investigator assigns each randomized treatment; and 3) ensuring that patient eligibility, investigator agreements, and informed patient consent are all in place before randomization. Informed consent is a vital component of ethical trial conduct, but its
proper delivery lies beyond the scope of this more statistical paper. We do note, however, that there are special challenges to obtaining consent in an emergency setting, for example, primary PCI in STEMI patients.
A central tenet is that the investigator cannot predict the assignment in advance because that could bias the choice of the next patient to be randomized.
The CONSORT guidelines state that a trial publication should document these randomization methods (41) . Allocation concealment Ensure treatment assignment cannot be predicted in advance of patient entry.
Double-blinding
Patients, investigators, and those evaluating outcome remain unaware of assigned treatment after randomization.
Single-blinding Investigators (and possibly patients) are aware of the assigned treatment, whereas those evaluating outcomes remain blinded. Superior to an unblinded design, but introduces greater opportunities for bias than a double-blind design.
Methods of randomization
Simple randomization Like coin tossing, with no connection between allocations. May lead to treatment imbalance in numbers or key patient factors.
Random permuted blocks
Treatment numbers are equal after each block of patients.
Order of treatments within each block is random. Block sizes may vary to avoid predictability if trial not double-blinded.
Stratification
Aims to ensure balance for key patient factors across treatment groups. Each combination of factors (e.g., center and sex) has its own random permuted blocks. Must avoid overstratification (e.g., 4 binary factors ¼ 16 strata), which may introduce imbalances.
Minimization A dynamic approach. Each treatment allocation is done to achieve the best balance across several patient factors.
Unequal randomization
Can allocate more patients on new treatment (e.g., 2:1 ratio). Increases knowledge of new treatment and may enhance investigator/patient enthusiasm. Requires more patients.
(Renal Denervation for Resistant Hypertension) trial of renal denervation versus a sham procedure in resistant hypertension had a 2:1 randomization ratio, whereas the HORIZONS-AMI trial in primary PCI had a 3:1 ratio of drug-eluting versus bare-metal stents (5, 47) . But, there is a loss of statistical power with unequal randomization. For example, for 3:2, 2:1, and 3:1 ratios, the total number of patients needs to increase by 4.2%, 12.5%, and 33.3%, respectively, to preserve the same power as a trial with equal randomization.
BLINDING
It is standard practice for drug trials to be doubleblind: that is, the patients and those responsible for their treatment and follow-up evaluation do not know which randomized treatment they are assigned (48, 49) . This is the optimal way to ensure that any as patient numbers. For instance, the PARADIGM-HF trial in chronic heart failure was planned to recruit 8,000 patients with a mean 34 months of follow-up.
For the composite primary endpoint of heart failure hospitalization and CV death, they anticipated an annual event rate of 14.5% on enalapril and had 97% power to detect a 15% relative risk reduction on LCZ696, with type I error of 0.05. Why set the power so high? They wanted good statistical power (80%) to also detect the same relative risk reduction in the secondary endpoint of CV death alone. A wise choice, in fact, because the published trial results showed marked treatment benefits for both outcomes (20) .
A cynical view of statistical power calculations is that people "juggle with the numbers" until they get the sample size they always wanted (or could afford).
There is an element of truth to this: there are practical limits on what is achievable patient recruitment.
Hence, some compromise is needed in not making the target so difficult as to put the consequent number of patients out of range for a real world study.
So, how can we "play with the numbers" while preserving scientific integrity? Take CHAMPION PHOENIX as an example (54) , and consider varying the parameters that feed into the calculations: An important fact when determining trial size is to recognize that statistical power depends mainly on the total number of patients in the trial experiencing the primary event during follow-up. Thus, some trials are event-driven, meaning that all patients are followed until that calendar date when the required number of events has occurred. Applying this logic, how many events should a trial aim for? A useful approximate formula is the following: one declares the hazard ratio (R) (or risk ratio) for the alternative hypothesis and its associated statistical power (1À b) (often 90% or 80%) and the 2-sided type I error (a) (usually 0.05).
Then, the total events required is calculated: 
Thus, if one wishes to detect a hazard ratio of 0.7 (i.e., a 30% relative risk reduction) with 80% power, then 252 total primary events are required. A much tougher challenge is to detect a hazard ratio of 0.85 (i.e., a 15% relative risk reduction) with 80% power because this requires a total of 1,194 primary events. 
